Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synflorix Effectiveness Against Invasive Pneumococcal Disease (FinIP)
NCT00861380Phase 3Completed
- Sponsor
- GSK
- Start
- May 2009
- Primary completion
- Jan 2012
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of 10-valent pneumococcal conjugate vaccine in invasive pneumococcal disease (IPD), pneumonia, acute otitis media (AOM), Haemophilus influenzae infection, sponsored by GSK. Started May 2009; status: completed.
02
Drugs
10-valent pneumococcal conjugate vaccine
03
Conditions
invasive pneumococcal disease (IPD)pneumoniaacute otitis media (AOM)Haemophilus influenzae infection
Beyond the preview
Go deeper on NCT00861380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00861380.